Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanoliposomal irinotecan + temozolomide
- Development stage
- Unknown
- Lead developer
- Brown University Oncology Group
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of nanoliposomal irinotecan (nal-IRI, also known as Onivyde) and temozolomide. Nanoliposomal irinotecan is a pegylated liposomal formulation of irinotecan designed to improve solubility, bioavailability, and blood-brain barrier penetration. This combination has been investigated primarily for recurrent glioblastoma and pediatric solid tumors, particularly Ewing sarcoma.
- Other names
- nal-IRI + temozolomidepegylated nanoliposomal irinotecan + temozolomideOnivyde + temozolomide
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on nanoliposomal irinotecan + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanoliposomal irinotecan + temozolomide.